Literature DB >> 15481978

Identification and specificity studies of small-molecule ligands for SH3 protein domains.

Steven R Inglis1, Cvetan Stojkoski, Kim M Branson, Jacquie F Cawthray, Daniel Fritz, Emma Wiadrowski, Simon M Pyke, Grant W Booker.   

Abstract

The Src Homology 3 (SH3) domains are small protein-protein interaction domains that bind proline-rich sequences and mediate a wide range of cell-signaling and other important biological processes. Since deregulated signaling pathways form the basis of many human diseases, the SH3 domains have been attractive targets for novel therapeutics. High-affinity ligands for SH3 domains have been designed; however, these have all been peptide-based and no examples of entirely nonpeptide SH3 ligands have previously been reported. Using the mouse Tec Kinase SH3 domain as a model system for structure-based ligand design, we have identified several simple heterocyclic compounds that selectively bind to the Tec SH3 domain. Using a combination of nuclear magnetic resonance chemical shift perturbation, structure-activity relationships, and site-directed mutagenesis, the binding of these compounds at the proline-rich peptide-binding site has been characterized. The most potent of these, 2-aminoquinoline, bound with Kd = 125 microM and was able to compete for binding with a proline-rich peptide. Synthesis of 6-substituted-2-aminoquinolines resulted in ligands with up to 6-fold improved affinity over 2-aminoquinoline and enhanced specificity for the Tec SH3 domain. Therefore, 2-aminoquinolines may potentially be useful for the development of high affinity small molecule ligands for SH3 domains.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15481978     DOI: 10.1021/jm049533z

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Synthetic ligands discovered by in vitro selection.

Authors:  S Jarrett Wrenn; Rebecca M Weisinger; David R Halpin; Pehr B Harbury
Journal:  J Am Chem Soc       Date:  2007-10-06       Impact factor: 15.419

2.  How much binding affinity can be gained by filling a cavity?

Authors:  Yuko Kawasaki; Eduardo E Chufan; Virginie Lafont; Koushi Hidaka; Yoshiaki Kiso; L Mario Amzel; Ernesto Freire
Journal:  Chem Biol Drug Des       Date:  2009-12-17       Impact factor: 2.817

3.  AlphaScreen HTS and live-cell bioluminescence resonance energy transfer (BRET) assays for identification of Tau-Fyn SH3 interaction inhibitors for Alzheimer disease.

Authors:  J Nicholas Cochran; Pauleatha V Diggs; N Miranda Nebane; Lynn Rasmussen; E Lucile White; Robert Bostwick; Joseph A Maddry; Mark J Suto; Erik D Roberson
Journal:  J Biomol Screen       Date:  2014-08-25

4.  Aminoquinoline-Rhodium(II) Conjugates as Src-Family SH3 Ligands.

Authors:  Samuel C Martin; Zachary T Ball
Journal:  ACS Med Chem Lett       Date:  2019-09-09       Impact factor: 4.345

5.  Potent and selective inhibition of SH3 domains with dirhodium metalloinhibitors.

Authors:  Farrukh Vohidov; Sarah E Knudsen; Paul G Leonard; Jun Ohata; Michael J Wheadon; Brian V Popp; John E Ladbury; Zachary T Ball
Journal:  Chem Sci       Date:  2015-06-03       Impact factor: 9.825

6.  Tandem Cu-catalyzed ketenimine formation and intramolecular nucleophile capture: Synthesis of 1,2-dihydro-2-iminoquinolines from 1-(o-acetamidophenyl)propargyl alcohols.

Authors:  Gadi Ranjith Kumar; Yalla Kiran Kumar; Ruchir Kant; Maddi Sridhar Reddy
Journal:  Beilstein J Org Chem       Date:  2014-05-28       Impact factor: 2.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.